Home › Funds › BAKER BROS. ADVISORS LP › CRNX
BAKER BROS. ADVISORS LP position in CRNX
CRINETICS PHARMACEUTICALS IN
BAKER BROS. ADVISORS LP reported holding 2,351,465 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$88.0M, representing 0.46% of its reported portfolio and ranking #28 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed CRNX holdings in 7 of the last 9 reported quarters, going back to Q2 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's CRNX position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in CRNX in Q2 2024 at 103,927 shares (US$4.7M). The position peaked in Q2 2026 at 2,351,465 shares, worth US$88.0M. Across 7 filings, BAKER BROS. ADVISORS LP increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 3 time(s). The most recent filing (Q2 2026) shows 2,351,465 shares valued at US$88.0M. Notable position changes include a 489% increase in Q4 2025, a 43% increase in Q1 2026.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 103.93K | $4.65M | New |
| Q3 2024 | 103.93K | $5.31M | Hold |
| Q2 2025 | 280.00K | $8.05M | New |
| Q3 2025 | 280.00K | $11.66M | Hold |
| Q4 2025 | 1.65M | $76.75M | Add |
| Q1 2026 | 2.35M | $85.41M | Add |
| Q2 2026 | 2.35M | $87.99M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRNX and 13F data
CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRNX
- Farallon Capital Management 8.99M sh · $336.37M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 8.99M sh · $336.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.46M sh · $241.87M · Q2 2026
- Bellevue Group AG 2.62M sh · $98.04M · Q2 2026
- Siren, L.L.C. 1.42M sh · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M sh · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M sh · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M sh · $44.39M · Q2 2026
- ORBIMED ADVISORS LLC 999.00K sh · $37.38M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held CRNX?
BAKER BROS. ADVISORS LP has disclosed CRNX holdings in 7 of the last 9 reported quarters, going back to Q2 2024.
What is BAKER BROS. ADVISORS LP's current position in CRNX?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 2.35M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $87.99M, representing 0.46% of its reported portfolio and ranking #28.
Has BAKER BROS. ADVISORS LP been buying or selling CRNX?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in CRNX. The position peaked in Q2 2026 at 2.35M shares.
Which other funds hold CRNX?
Other major institutional holders of CRNX include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., DRIEHAUS CAPITAL MANAGEMENT LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.